Clinical Trial

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 8, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-23.
Trial Details
NCT Number NCT06010862
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Collaborators: The First Affiliated Hospital of Nanchang University
Conditions Gastric Cancer, Colon Cancer, Pancreas Cancer, Esophagus Cancer, Cholangiocarcinoma, Lung Cancer, Breast Cancer
Enrollment 36 participants
Start Date 2023-09-30
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2023-11-08